BioScrip Announces Steps To Enhance Shareholder Value
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/28/2026
- Wall Street ends mixed as investors focus on tech earnings
- NVIDIA’s rising CDS the talk of Wall Street amid circular financing fears
- Market watchers weigh chances of a surprise Fed rate hike tomorrow
- U.S. chip stocks extend losses on AI financing, China competition fears
- Tesla to buy power from Arizona solar project
- Visa (V) To Cut 7% Of Its Workforce, Totaling About 2,600 Jobs - Bloomberg
- BTIG Upgrades Outlook Therapeutics Inc. (OTLK) to Buy
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- Carpenter Technology CEO Brian Malloy passes; Tony Thene returns as CEO
- Applied Digital (APLD) Tops Q4 EPS by 23c, Revenue Beats
BioScrip (BIOS) Posts Q2 GAAP Loss of $3.60/Share; Will Review Strategic Alternatives
August 10, 2015 7:06 AM EDTBioScrip (NASDAQ: BIOS) reported Q2 EPS of ($3.60), which may not compare with the analyst estimate of ($0.08). Revenue for the quarter came in at $262.4 million versus the consensus estimate of $269.38 million.
Consolidated Adjusted EBITDA was a loss of $2.5 million, a $13.5 million decrease compared to Adjusted EBITDA of $11.0 million in the prior year period. The decrease was primarily due to a lower gross margin revenue mix shift as well as the increase of contractual and bad debt expense; and
BioScrip announced a multi-step plan to enhance shareholder value, improve financial flexibility and position... More
